Additional more detailed summary of responsibilities include: Draft, review, and negotiate a wide variety of agreements, including but not limited to: clinical trial agreements (CTAs), master service agreements (MSAs) and statements of work with CROs and clinical sites, confidentiality/non-disclosure agreements, material transfer agreements (MTAs), consulting and advisory agreements, manufacturing and supply agreements, quality agreements, licensing and collaboration agreements, and vendor/procurement contracts. Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform.